Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The Canadian Bioceutical CBICF

MPX Bioceutical Corp is a Canada based company involved in the natural health products industry. It is engaged in the manufacture and distribution of nutraceuticals to the North American marketplace and providing financial and business expertise to emerging corporations primarily in the pharmaceutical, medical and biotechnology industries. The company provides management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to two medicinal cannab


GREY:CBICF - Post by User

Comment by CWattB89on Aug 30, 2018 10:10am
58 Views
Post# 28541922

RE:awful report

RE:awful reportnot sure what the goal of this post is? the entire weed industry is brand new and ignores fundamental F/S analysis. So you decide to post your own here for what reason...?
cueball40 wrote: u guys  know  how  to  read a  report... they  lost  11  million  dollars.. The Company recorded a net comprehensive loss of $11.0 million for the three months ended June 30, 2018, as compared to a net comprehensive loss of $2.3 million for the three months ended June 30, 2017. The basic and diluted loss per MPX share for the three months ended June 30, 2018 totaled $0.03 versus $0.01 for the comparable period. The increase in net comprehensive loss is primarily attributed to loss from operations of $5.1 million, interest and financing charges of $2.3 million relating to interest on the ZQ Promissory Note and Hi-Med facility and financing costs for the convertible loan allocated to the conversion options and changes in the fair value of derivative liability of $2.6, million primarily related to the Hi-Med Facility.


<< Previous
Bullboard Posts
Next >>